

BUY**TP: Rs 2,109 | ▲ 32%****SUN PHARMA**

| Pharmaceuticals

| 01 February 2026

All round beat; growth momentum to continue

- Domestic sales growth driven by volume growth of 6.3% vs IPM volume growth of 1.2% due to leadership position across 14 categories
- Global innovative sales ex-of milestone income contributed 21% of total sales, with milestone contribution increasing to 24% of total sales
- On a strong innovative portfolio, we continue to ascribe a PE of 34x and roll forward to Dec'27 EPS to arrive at TP of Rs 2,109. Maintain BUY

Foram Parekh
 Research Analyst
research@bobcaps.in

Earnings upbeat – Sales grew by 13% YoY to Rs 155 bn, driven by year-on-year growth of 16% in the domestic region, 28% in emerging markets (EMs), 21% in the ROW region and 6% in the US region; which was offset by 5% decline in the API sales. During the quarter, there was a milestone income of USD55mn from the ROW market (Rs4.9bn), excluding which the sales rose by 10% YoY. Healthy product mix led to an all-time high Gross Margin of 81% and EBITDA margin of 30.9%. However, excluding for the milestone income, Gross Margin was at 80.4% and EBITDA Margin at 28.6%. During the quarter, there was an exceptional item of Rs 4.8bn recorded, where Rs 3.7bn was allotted to the International Labour Code and the balance to GSMDL settlement. Adjusting against milestone and exceptional costs, PAT reported 6% decline YoY to Rs 32.1bn.

Global innovative sales on new launches – During the quarter, SUNP's global innovative sales went up by 14% YoY to USD 423 mn. Sun also witnessed a growth of 22% YoY to USD 55 mn in its milestone income from the RoW region, while ex-of milestone, global innovative sales rose by 13% to USD 368 mn. The growth was driven by new launches like Unloxcyt and Ilumya in the US and domestic regions, respectively. Global innovative sales gaining traction from both US and non-US regions, thereby clocking sales of USD 1bn in 9MFY26, ex-of milestone. As both the newly launched drugs are witnessing healthy early feedback, we expect FY26E global innovative sales to report USD ~1.4bn.

Domestic region continues to grow in double digits – Domestic sales were 5% above our estimates to Rs 50bn. The growth is driven by volume growth of 6.3% vs IPM volume growth of 1.2% and 12 new launches during the quarter. Volume growth was driven by sustaining leadership position in Rx across 14 Dr's categories. This has led to increase in Sun's market share to 8.4% as on Dec'25 MAT vs the earlier market share of 8.1%. Going forward, SUNP is expected to launch Semaglutide injectables on the 1st day of LoE and expects enhanced access to the product. Given its unwavering leadership in the IPM, we expect Sun to continue surpassing IPM growth and report 12% CAGR from FY26-28E to Rs 243.5bn in FY28E.

Key changes

Target	Rating
▲	◀ ▶

Ticker/Price	SUNP IN/Rs 1,595
Market cap	US\$ 41.6bn
Free float	45%
3M ADV	US\$ 40.9mn
52wk high/low	Rs 1,851/Rs 1,548
Promoter/FPI/DII	54%/16%/20%


Source: NSE | Price as of 30 Jan 2026

Key financials

Y/E 31 Mar	FY25A	FY26E	FY27E
Total revenue (Rs mn)	525,785	580,124	639,439
EBITDA (Rs mn)	153,869	168,339	193,436
Adj. net profit (Rs mn)	118,260	118,199	137,519
Adj. EPS (Rs)	49.3	49.3	57.3
Consensus EPS (Rs)	49.3	48.3	55.3
Adj. ROAE (%)	16.9	15.2	15.6
Adj. P/E (x)	32.4	32.4	27.8
EV/EBITDA (x)	26.5	24.6	22.0
Adj. EPS growth (%)	16.2	(0.1)	16.3

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE



EM sales continues to ramp up - EM reported 7% growth above our estimates to Rs 30 bn. In INR terms, the region grew by 28%, however, in cc terms the region grew by 13%. The growth was driven by generics as well as innovative products, currency tailwinds and pickup in regions like Romania, South Africa and Brazil. We anticipate EMs to grow at a CAGR of 9% in FY26-28E to Rs 121bn in FY28E.

EBITDA Margin increased due to milestone income – During the quarter, EBITDA Margin reported at 30.9% due to 24% contribution from the global innovative products. Ex of milestone income of USD 55mn, EBITDA Margin reported at 28.6% that came from 21% contribution from the global innovative products. Overall, margins continue to be led by healthy traction in both branded domestic business and global innovative products. We expect global innovative sales contribution to reach ~25% by FY28E, thus expect EBITDA Margin to increase to 31% by FY28E.

Valuations - We have raised our EPS estimates by 2.4%, 3.3% and 4.1% for FY26E, FY27E and FY28E as earnings were above estimates. We model in sales/EBITDA /PAT CAGR of 10%/13%/15% respectively from FY26-28E, factoring in ~12% domestic sales CAGR from FY26-28E. We also believe global innovative portfolio sales to continue the upward momentum as sales of newly launched products like Unloxcyt and Leqselvi picks up in the US and Ilumya in India, Thus, we believe, the innovative portfolio contribution of ~25% by FY28E, to enable EBITDA Margin increasing to 31% by FY28E. Hence, we maintain our ascribed PE of 34x and roll forward to Dec'27 EPS to arrive at TP of of Rs 2,109. Maintain BUY.

Financial Highlights

Fig 1 – Quarterly snapshot

(Rs mn)	Q3FY26	Q3FY25	YoY (%)	Q2FY26	QoQ (%)	BoB est.	Var. (%)
Net Sales	155,205	136,755	13.5	144,783	7.2	143,298	8.3
Total Expenses	107,260	94,831	13.1	103,817	3.3		
(%) of net sales	69	69		72			
Raw material consumed	29,451	27,405	7.5	29,827	(1.3)		
(%) of net sales	19.0	20		21			
Staff cost	28,920	25,523	13.3	27,648	4.6		
(%) of net sales	18.6	18.7		19.1			
R&D cost	8,928	8,450	5.7	7,827	14.1		
(%) of net sales	5.8	6.2		5.4			
SG&A	39,961	33,453	19.5	38,516	3.8		
(%) of net sales	25.7	24.5		26.6			
EBITDA	47,946	41,924	14.4	40,966	17.0	39,264	22.1
PBT	45,627	39,759	14.8	37,371	22.1		
Less: Taxation	8,261	5,589		10,305			
PAT	37,367	34,171	9.4	26,875	39.0	25,159	48.5
Less: Minority Interest	323	141		191			
Exceptional items	(3,355)	(4,995)		4,305			
PAT attributable to shareholders	33,689	29,034	16.0	31,180	8.0	25,159	33.9
Key Ratios (%)							
Gross Margin	81.0	80.0	106	79.4	163		
EBITDA Margin	30.9	30.7	24	28.3	260	27.4	
Tax / PBT	18.1	14.1	405	27.6	(947)		
NPM	24.1	25.0	(91)	18.6	551	17.6	
EPS (Rs)	14.0	12.1	16.0	13.0	8.0	12.0	16.6

Source: Company, BOBCAPS Research


Fig 2 – Revenue Segment

(Rs mn)	Q3FY26	Q3FY25	YoY (%)	Q2FY26	QoQ (%)	BoB est.	Var. (%)
Formulation	148,880	128,258	16.1	139,418	6.8	135,631	9.8
Domestic	49,986	43,004	16.2	47,348	5.6	47,770	4.6
Exports	98,895	85,254	16.0	92,070	7.4	87,861	12.6
US	42,505	40,030	6.2	43,288	(1.8)	42,594	(0.2)
EM & ROW	56,390	45,224	24.7	48,782	15.6	45,267	24.6
EM	29,996	23,384	28.3	22,561	33.0	27,952	7.3
ROW	26,394	21,840	20.8	17,340	52.2	17,797	48.3
APIs and others	5,810	6,112	(4.9)	4,635	25.4	6,009	(3.3)
Net Sales	154,691	134,369	15.1	144,052	7.4	141,640	9.2
OOI	515	2,385	NA	731	NA	1,657	(68.9)
Revenue	155,205	136,755	13.5	144,783	7.2	143,298	8.3

Source: Company, BOBCAPS Research


Financials in Charts

Fig 3 – Revenue growth on global innovative and branded domestic sales




Source: Company, BOBCAPS Research

Fig 4 – EBITDA growth on healthy product mix




Source: Company, BOBCAPS Research

Fig 5 – EBITDA Margin increase aided by milestone income




Source: Company, BOBCAPS Research

Fig 6 – APAT growth driven by healthy operations




Source: Company, BOBCAPS Research

Fig 7 – Global innovative sales led by milestone income



Source: Company, BOBCAPS Research

Fig 8 – PAT growth sequentially on new launches



Source: Company, BOBCAPS Research

Earnings call highlights

Guidance

- Management has guided the effective tax rate (ETR) to remain around 25% for FY26.

US Business

- Performance:** US formulation sales were **USD 477 mn**, reflecting muted growth as innovative medicines growth offset pressure in generics, due to product-specific competition. The US contributed **27.5% of consolidated sales**.
- Outlook:** Management expects innovative medicines to continue scaling, while the generics business should recover as compliance issues across sites are resolved and new approvals come through.
- Launches:** Three new products were launched during the quarter.
- gRevlimid:** Contribution remained negligible in Q3FY26.

Domestic Business

- Performance:** India Formulation sales reached **Rs50.0 bn**, growing **16.2% YoY**, contributing **32.3% of total sales**. Sun Pharma retained its **#1 rank**, with market share increasing from **8.1% to 8.4%** (Pharmarack MAT Dec'25). As per SMSRC (Jul–Oct 2025), the company ranked #1 in prescriptions across **14 doctor specialties**. Growth outpaced the overall IPM and was broad-based across therapies.
- Launches:** 12 new products were launched during the quarter, including Ilumya in India.
- Volume & NPI:** Volume growth stood at **6.3%**, significantly ahead of IPM's **1.2%**, with growth driven primarily by volumes and new launches.
- GLP-1:** The company plans to launch **Semaglutide** immediately upon patent expiry in India and expects to be among the day-1 entrants. Regulatory approvals have already been received for both Obesity and type-2 Diabetes under **Noveltreat** and **Sematrinity** respectively. Management indicated adequate supply readiness and plans to expand field force support.

Emerging Markets

- Accounted for 19.4% of revenue, delivering 13% CC growth, driven by broad-based performance in generics and innovative medicines, supported by currency tailwinds. Romania, South Africa, and Brazil performed well in local currencies.

Valuation Methodology

We have raised our EPS estimates by 2.4%, 3.3% and 4.1% for FY26E, FY27E and FY28E as earnings were above estimates. We model in sales/EBITDA /PAT CAGR of 10%/13%/15% respectively from FY26-28E, factoring in ~12% domestic sales CAGR from FY26-28E. We also believe global innovative portfolio sales to continue the upward momentum as sales of newly launched products like Unloxcyt and Leqselvi picks up in the US and Ilumya in India, Thus, we believe, the innovative portfolio contribution of ~25% by FY28E, to enable EBITDA Margin increasing to 31% by FY28E. Hence, we maintain our ascribed PE of 34x and roll forward to Dec'27 EPS to arrive at TP of of Rs 2,109. Maintain BUY.

Fig 9 – Change in Estimates

(Rs mn)	New			Old			Change (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Sales	580,124	639,439	705,051	568,655	621,929	680,513	2.0	2.8	3.6
EBITDA	168,339	193,436	216,810	164,843	188,139	209,264	2.1	2.8	3.6
EBITDA margin (%)	29.0	30.3	30.8	29.0	30.3	30.8	2.95	0.01	0.00
PAT	118,199	137,519	155,590	115,328	133,166	149,399	2.5	3.3	4.1
EPS (Rs)	49.3	57.3	64.9	48.1	55.5	62.3	2.4	3.3	4.1

Source: Company, BOBCAPS Research


Key Risks

Key downside risks to our estimates:

- Slow pick up in sales of newly launched products Unloxcyt and Leqselvi
- Continued regulatory hindrances to the plants under USFDA scrutiny
- Deterioration in the US generic pricing environment


Valuation Bands

Fig 10 – PE Band




Source: Bloomberg

Fig 11 – EV/EBITDA Band




Source: Bloomberg

Fig 12 – P/B Band




Source: Bloomberg

Fig 13 – EV/Sales Band




Source: Bloomberg

Fig 14 – Sun Pharma vs Nifty Pharma



Source: Bloomberg

Fig 15 – Sun Pharma vs Nifty 50



Source: Bloomberg

Financials

Income Statement

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Total revenue	484,969	525,785	580,124	639,439	705,051
EBITDA	129,884	153,869	168,339	193,436	216,810
Depreciation	25,566	25,736	26,977	28,279	29,647
EBIT	104,317	128,133	141,362	165,157	187,163
Net interest inc./(exp.)	(2,385)	(2,314)	(1,303)	(1,040)	(843)
Other inc./(exp.)	13,542	19,650	17,215	18,975	20,922
Exceptional items	0	0	0	0	0
EBT	115,474	145,470	157,275	183,092	207,242
Income taxes	14,395	27,720	39,586	46,084	52,163
Extraordinary items	(5,305)	(8,634)	0	0	0
Min. int./Inc. from assoc.	(721)	(511)	(511)	(511)	(511)
Reported net profit	96,496	109,626	118,199	137,519	155,590
Adjustments	5,305	8,634	0	0	0
Adjusted net profit	101,801	118,260	118,199	137,519	155,590

Balance Sheet

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Accounts payables	56,533	61,843	66,436	73,930	81,515
Other current liabilities	36,579	44,373	44,565	44,777	45,009
Provisions	57,715	66,202	72,357	79,127	86,575
Debt funds	32,737	23,622	18,612	14,855	12,037
Other liabilities	0	0	0	0	0
Equity capital	2,399	2,399	2,399	2,399	2,399
Reserves & surplus	669,546	722,460	824,251	936,634	1,063,832
Shareholders' fund	671,945	724,860	826,650	939,033	1,066,232
Total liab. and equities	855,508	920,899	1,028,620	1,151,722	1,291,369
Cash and cash eq.	98,919	116,208	183,663	264,832	347,435
Accounts receivables	112,494	130,461	131,919	143,655	158,395
Inventories	98,683	102,433	103,310	105,113	115,899
Other current assets	102,335	95,956	95,956	95,956	95,956
Investments	150,258	183,538	207,080	232,975	261,462
Net fixed assets	109,090	100,359	108,106	103,294	98,288
CWIP	53,539	66,440	73,084	80,392	88,431
Intangible assets	130,191	125,503	125,503	125,503	125,503
Deferred tax assets, net	0	0	0	0	0
Other assets	0	0	0	0	0
Total assets	855,508	920,899	1,028,620	1,151,721	1,291,369

Cash Flows

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Cash flow from operations	132,005	146,594	149,704	161,856	169,310
Capital expenditures	(24,688)	(37,591)	(28,994)	(30,776)	(32,680)
Change in investments	(1,957)	(33,280)	(18,354)	(20,189)	(22,208)
Other investing cash flows	0	0	0	0	0
Cash flow from investing	(26,645)	(70,872)	(47,348)	(50,965)	(54,888)
Equities issued/Others	0	0	0	0	0
Debt raised/repaid	(36,122)	(9,115)	(5,010)	(3,757)	(2,818)
Interest expenses	(2,385)	(2,314)	(1,303)	(1,040)	(843)
Dividends paid	(17,387)	(19,753)	(21,297)	(24,778)	(28,035)
Other financing cash flows	(7,810)	(39,624)	5,081	(145)	(124)
Cash flow from financing	(63,703)	(70,805)	(22,529)	(29,721)	(31,819)
Chg in cash & cash eq.	41,657	4,916	79,828	81,169	82,602
Closing cash & cash eq.	98,919	103,835	183,663	264,832	347,435

Per Share

Y/E 31 Mar (Rs)	FY24A	FY25A	FY26E	FY27E	FY28E
Reported EPS	40.2	45.7	49.3	57.3	64.9
Adjusted EPS	42.4	49.3	49.3	57.3	64.9
Dividend per share	7.2	8.2	8.9	10.3	11.7
Book value per share	265.8	301.0	343.6	390.6	0.0

Valuations Ratios

Y/E 31 Mar (x)	FY24A	FY25A	FY26E	FY27E	FY28E
EV/Sales	8.3	7.7	7.2	6.6	6.2
EV/EBITDA	30.8	26.5	24.6	22.0	20.1
Adjusted P/E	37.6	32.4	32.4	27.8	24.6
P/BV	6.0	5.3	4.6	4.1	

DuPont Analysis

Y/E 31 Mar (%)	FY24A	FY25A	FY26E	FY27E	FY28E
Tax burden (Net profit/PBT)	88.2	81.3	75.2	75.1	75.1
Interest burden (PBT/EBIT)	110.7	113.5	111.3	110.9	110.7
EBIT margin (EBIT/Revenue)	21.5	24.4	24.4	25.8	26.5
Asset turnover (Rev./Avg TA)	14.6	14.8	14.9	14.7	14.4
Leverage (Avg TA/Avg Equity)	1.3	1.3	1.3	1.2	1.2
Adjusted ROAE	16.1	16.9	15.2	15.6	15.5

Ratio Analysis

Y/E 31 Mar	FY24A	FY25A	FY26E	FY27E	FY28E
YoY growth (%)					
Revenue	10.5	8.4	10.3	10.2	10.3
EBITDA	6.7	18.5	9.4	14.9	12.1
Adjusted EPS	18.8	16.2	(0.1)	16.3	13.1

Profitability & Return ratios (%)

EBITDA margin	26.8	29.3	29.0	30.3	30.8
EBIT margin	21.5	24.4	24.4	25.8	26.5
Adjusted profit margin	21.0	22.5	20.4	21.5	22.1
Adjusted ROAE	16.1	16.9	15.2	15.6	15.5
ROCE	15.1	16.4	14.8	16.2	16.3

Working capital days (days)

Receivables	85	84	83	82	82
Inventory	77	70	65	60	60
Payables	205	207	209	211	211

Ratios (x)

Gross asset turnover	1.3	1.3	1.4	1.5	1.5
Current ratio	2.7	2.6	2.8	3.1	3.4
Net interest coverage ratio	43.7	55.4	108.5	158.8	222.1
Adjusted debt/equity	(0.3)	(0.4)	(0.5)	(0.5)	(0.6)

Source: Company, BOBCAPS Research | Note: TA = Total Assets

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**

Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**

SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025**

Brand Name: **BOBCAPS**

Trade Name: **www.barodaetrade.com**

CIN: **U65999MH1996GOI098009**



Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%


HOLD – Expected return from -6% to +15%

SELL – Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): SUN PHARMA (SUNP IN)



B – Buy, H – Hold, S – Sell, A – Add, R – Reduce

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an “as is” basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the “Losses”) which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom (“UK”):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd (“MSL”) who is authorised and regulated by the Financial Conduct Authority (“FCA”) in the United Kingdom (MSL and its affiliates are collectively referred to as “MAYBANK”). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the “Order”), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as “relevant persons”).

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.